Hookipa Pharma (NASDAQ:HOOK) Trading Up 2.7% – Should You Buy?

Posted by Jon Anderson on Apr 12th, 2025

Hookipa Pharma Inc (NASDAQ:HOOK – Get Free Report)’s stock price traded up 2.7% during trading on Friday . The stock traded as high as $0.81 and last traded at $0.76. 17,620 shares changed hands during trading, a decline of 76% from the average session volume of 73,896 shares. The stock had previously closed at $0.74.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. HC Wainwright restated a “neutral” rating on shares of Hookipa Pharma in a report on Friday, January 10th. Royal Bank of Canada cut shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and reduced their target price for the stock from $48.00 to $2.00 in a research report on Friday, December 20th.

Read Our Latest Research Report on HOOK

Hookipa Pharma Price Performance

The stock has a 50-day moving average price of $1.33 and a 200-day moving average price of $2.30. The firm has a market capitalization of $9.16 million, a PE ratio of -0.20 and a beta of 0.78.

Institutional Investors Weigh In On Hookipa Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Gilead Sciences Inc. purchased a new position in shares of Hookipa Pharma during the 4th quarter valued at approximately $3,771,000. Millennium Management LLC acquired a new stake in Hookipa Pharma in the fourth quarter valued at $31,000. Finally, Squarepoint Ops LLC bought a new position in Hookipa Pharma during the 4th quarter valued at $104,000. 63.88% of the stock is currently owned by hedge funds and other institutional investors.

Hookipa Pharma Company Profile

(Get Free Report)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.